News and Trends 26 Oct 2016 Proteins can now Sing about their Anomalies to help cure Diseases Researchers are generating melodies from proteins’ structures. It could be used to understand protein folding and anomalies that contribute to disease. Protein folding is an infamously difficult phenomenon to understand and predict from sequence data. A collaboration between a resident composer at the University of Tempere in Finland and a scientist at the Francis Crick […] October 26, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2016 Can this new Antibody-Drug Conjugate Collaboration make it to the Top? Nordic Nanovector is collaborating with Heidelberg Pharma to access the promising antibody-drug conjugate (ADC) technology. However, can it really take on the strong competition? Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat Non-Hodgkin Lymphoma (NHL) and other blood cancers. Today, the company has announced a collaboration with Wilex’ subsidiary Heidelberg Pharma to incorporate antibody-drug conjugates (ADCs) […] October 26, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2016 Biosimilars are all the rage, but how do they compare to Generics? Biosimilars could be the future of the pharmaceutical industry, as the market could grow 10-fold in the next 5 years. But how do they differ from generic drugs? During the past decade, Europe saw the emergence of a new type of drug: biosimilars. The concept of a “similar biological medicinal product” was adopted in EU […] October 26, 2016 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 25 Oct 2016 The First Peanut Allergy Therapy might soon hit the Shelves DBV Technologies announced outstanding Phase IIb results for Viaskin Peanut, which could be the first-ever commercial peanut allergy therapy in the near future. However, competition is stiff. DBV Technologies, the first French Biotech to enter the NASDAQ, aims to be the first to attain approval for a food allergy therapy. The company’s lead pipeline candidate […] October 25, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 25 Oct 2016 This Diagnostic Tool beats the Standard for Respiratory Infection Tests Curetis is drastically reducing the time required to test for severe infectious diseases. The newest incorporation is expected early next year and could soon substitute the hospital standards. Curetis is a German biotech that commercializes diagnostic technologies for infectious diseases. After a very successful IPO last year, the company is advancing its Unyvero platform for fast diagnostics. The […] October 25, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 25 Oct 2016 Meet the Cyborg Bacteria that Culture Themselves What if you could program your bacteria to grow in any pattern you fancy? Researchers from ETH Zurich can, and this is huge news for the Biotech Industry! Scientists from ETH Zurich have developed a fully automated system that can precisely control bacterial growth using light. What’s more, unlike other prototypes, this system can adjust to any […] October 25, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Sponsored 25 Oct 2016 7 Considerations for Commercializing a New Drug So you have exciting science, but do you know if it will be a commercial success? Ask the drug development and commercialization experts, who have turned the pharma analytics and consultancy industry on its head! We sat down with Mirador Analytics, to talk about bringing a drug from the clinic to the market. They are […] October 25, 2016 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2016 A €103M Target to Reduce Drug Dosage with a Slow-Release Tech Ascendis aims to raise €103M ($112M) for Phase III trials in Growth Hormone Deficiency (GHD) that offer children a weekly alternative to daily injections. After its IPO on NASDAQ last year, the Danish Ascendis is making an underwritten public offering in the US that aims to raise €103M ($112M) to advance its TransCon pipeline. The funds will be directed to […] October 24, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2016 Here comes the First-ever Combination Therapy for Multiple Sclerosis Actelion is overcoming the upcoming expiration of one of its most profitable patents and it’s using its strong position to make the leap into the crowded market of multiple sclerosis with the first-ever combination therapy. Actelion is one of the top billion-euro Biotechs in Europe and a leader in pulmonary arterial hypertension (PAH). Although the patent for […] October 24, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2016 The Colours of Biotech: Who’s Doing What in the European Ecosystem in an Infographic Happy Monday! Our colleague, Justine, has put together a wonderful infographic to map out which European biotech companies are making moves in which field, from health to agrotech to medtech. Its vivid colours will surely brighten your day – take a look-see below! Justine is pursuing a PhD at the Heinrich Heine Universität in Düsseldorf after obtaining […] October 24, 2016 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 22 Oct 2016 Meet the Bioartist that wants to Replace all your Furniture with… Fungi! Can you imagine a future where everything in your daily life is made out of fungi..? It’s actually not such a stretch idea: this bioartist is showing the world all these microorganisms can do. Maurizio Montalti is an artist that uses fungi to build his own furniture and homeware. In 2010, he founded Officina Corpuscoli in Amsterdam […] October 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Oct 2016 New Partnership comes to the Rescue in Neurological Diseases Developing effective treatments for neurological diseases is a big challenge in medicine. But here come UCB and Evotec with a new partnership that could help those suffering from epilepsy and Parkinson’s. UCB is a Biotech from Brussels that focuses on neurological and immune diseases. The company has multiple products on the market, including an antibody drug for arthritis and […] October 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email